| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Legal Officer | Sr. VP & General Counsel
1 company
Nathaniel S. Gardiner last filed a Form 4 in February 2024, as Chief Legal Officer at ENTA. Nathaniel S. Gardiner's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 75,688 shares of ENTA. The ENTA filings lean toward selling, a net 3,782 shares.
Nathaniel S. Gardiner has 37 Form 4 filings on record from February 2015 to February 2024, all as Chief Legal Officer at Enanta Pharmaceuticals (ENTA), 2015–2024.
The 59 reported transactions were 16 option exercises, 15 stock awards, 12 tax withholdings and 10 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $59K and 2 sales worth about $335K.
The largest open-market purchase was 1,400 shares of ENTA at an average $33.23 on February 17, 2015, about $47K.
The largest open-market sale was 3,270 shares of ENTA at an average $95.28 on February 13, 2019, about $312K.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2023 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & General Counsel | Sell | 2,412 | $9.63 | $23,227.56 | -3.4% | +65.3% | -9.9% | |
| Feb 13, 2019 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & General Counsel | Sell | 3,270 | $95.28 | $311,562.33 | -12.0% | - | - | |
| May 11, 2016 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & General Counsel | Buy | 500 | $24.45 | $12,222.50 | +35.7% | - | - | |
| Feb 17, 2015 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & General Counsel | Buy | 1,400 | $33.23 | $46,522.00 | New | - | - |